tiprankstipranks
Trending News
More News >

Regeneron downgraded at RBC Capital after ‘disappointing’ itepekimab results

As previously reported, RBC Capital downgraded Regeneron (REGN) to Sector Perform from Outperform with a price target of $662, down from $943, following “disappointing” itepekimab results given the firm’s sense that the path forward for that drug “may be limited.” The firm still likes the long-term prospects of the company’s R&D engine and believes shares are likely fundamentally undervalued, so it “would not be surprised to see shares rebound off of lows.” However, RBC believes substantial outperformance in the near term beyond this would require success of a pipeline drug with similar multi-billion dollar potential to itepekimab and/or “major and well-received” external business development, which does not “seem imminent,” the analyst tells investors.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue